Skip to Main Content

Hope S. Rugo


Breast oncologist

Dr. Hope Rugo is a hematologist-oncologist who specializes in breast cancer treatment. She joined the UCSF Carol Franc Buck Breast Care Center after a decade at UCSF Medical Center, where she worked in bone marrow transplantation for a variety of diseases, including breast cancer.

Rugo is co-director of UCSF's breast cancer clinical trials program. She is the principal investigator for several clinical trials of potential new therapies. She is also an investigator with the Bay Area's SPORE (Specialized Programs of Research Excellence) on breast cancer. The National Cancer Institute established SPORE to foster collaborative, interdisciplinary cancer research.

  • Education

    University of Pennsylvania School of Medicine, 1984

  • Residencies

    UCSF Medical Center, Internal Medicine, 1987

  • Fellowships

    UCSF Medical Center, Hematology, 1990

    UCSF Medical Center, Oncology, 1995

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title


  • Languages



Where I see patients (1)

    My reviews


    Overall Experience
    310 Ratings
    Explained things in a way that was easy to understand
    306 Ratings
    Did the doctor pay attention to your concerns
    305 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    300 Ratings
    Knew the important information about your medical history
    307 Ratings
    The provider showed respect for what you had to say
    310 Ratings
    The provider spent enough time with me
    310 Ratings
    Decorative Caduceus

    T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk H...

    A Kaplan-Meier method will be used to estimate the survival curves and a stratified log-rank test will be used to compare the invasive disease-free survival (iDFS) of the two arms. A stratified Cox model will be used to estimate t...


    Decorative Caduceus

    A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Can...

    IDFS excluding second non-breast primary invasive cancers


    Decorative Caduceus

    ATEMPT 2.0: Adjuvant T-DM1 vs TH

    Compare the incidence of clinically relevant toxicities (CRT) in patients with Stage I HER2-positive breast cancer treated with trastuzumab emtansine followed by trastuzumab SC to the incidence in those treated with paclitaxel in ...


    Decorative Caduceus

    Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).

    Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.


    Decorative Caduceus

    Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo...

    The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of se...


    Decorative Caduceus

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants W...


    Decorative Caduceus

    Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    Clearance of tumor cfDNA after 18 weeks, it will be tested using a one-sided one-sample binomial exact test (alpha 5%) against a null hypothesis value of 7% false negatives.


    Decorative Caduceus

    Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    Dose-limiting toxicities (DLTs)


    Decorative Caduceus

    The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanc...

    Progression Free Survival is defined from the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST 1.1 or death from any cause, whichever occurs first.


    Decorative Caduceus

    Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Br...

    Progression-Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression as assessed by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death due to any cause, ...